Next 10 |
home / stock / eras / eras articles
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on disco...
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Thursday. Shares of e.l.f. Beauty, Inc. (NYSE:ELF) rose sharply durin...
The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern a...
U.S. stock futures were slightly lower this morning, with the Dow futures falling around 10 points on Friday. Shares of DXC Technology Company (NYS...
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm col...
SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focu...
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on disc...
The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around th...
The Dow Jones closed lower by around 70 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around...
News, Short Squeeze, Breakout and More Instantly...
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to date Favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma Randomi...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., cha...
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed und...